These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 1421556)

  • 1. Depo provera treatment for sex offending behavior: an evaluation of outcome.
    Meyer WJ; Cole C; Emory E
    Bull Am Acad Psychiatry Law; 1992; 20(3):249-59. PubMed ID: 1421556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medroxyprogesterone treatment for paraphiliacs.
    Kravitz HM; Haywood TW; Kelly J; Wahlstrom C; Liles S; Cavanaugh JL
    Bull Am Acad Psychiatry Law; 1995; 23(1):19-33. PubMed ID: 7599368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholelithiasis associated with medroxyprogesterone acetate therapy in men.
    Meyer WJ; Wiener I; Emory LE; Cole CM; Isenberg N; Fagan CJ; Thompson JC
    Res Commun Chem Pathol Pharmacol; 1992 Jan; 75(1):69-84. PubMed ID: 1385654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depo-Provera in adolescents: effects of early second injection or prior oral contraception.
    Harel Z; Biro FM; Kollar LM
    J Adolesc Health; 1995 May; 16(5):379-84. PubMed ID: 7662688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medroxyprogesterone and paraphiles: do testosterone levels matter?
    Kravitz HM; Haywood TW; Kelly J; Liles S; Cavanaugh JL
    Bull Am Acad Psychiatry Law; 1996; 24(1):73-83. PubMed ID: 8891323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose oral medroxyprogesterone acetate in the management of the paraphilias.
    Gottesman HG; Schubert DS
    J Clin Psychiatry; 1993 May; 54(5):182-8. PubMed ID: 8509348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug treatment of paraphilic and nonparaphilic sexual disorders.
    Guay DR
    Clin Ther; 2009 Jan; 31(1):1-31. PubMed ID: 19243704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depo Provera. Position paper on clinical use, effectiveness and side effects.
    Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
    Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of sex offenders with Depo-Provera.
    Kiersch TA
    Bull Am Acad Psychiatry Law; 1990; 18(2):179-87. PubMed ID: 2142608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Policing "perversions": Depo-Provera and John Money's new sexual order.
    Tsang DC
    J Homosex; 1995; 28(3-4):397-426. PubMed ID: 7560938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemical castration: MPA treatment of the sexual offender.
    Fitzgerald EA
    Am J Crim Law; 1990; 18(1):1-60. PubMed ID: 15991431
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of depo-provera in the treatment of aggressive sexual offenders: preliminary report of three cases.
    Barry DJ; Ciccone JR
    Bull Am Acad Psychiatry Law; 1975; 3(3):179-84. PubMed ID: 1230194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of the role of two antilibidinal drugs in the treatment of sex offenders with mental retardation.
    Cooper AJ
    Ment Retard; 1995 Feb; 33(1):42-8. PubMed ID: 7707938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy (recombinant interleukin 2), hormone therapy (medroxyprogesterone acetate) and antioxidant agents as combined maintenance treatment of responders to previous chemotherapy.
    Mantovani G; Maccio A; Madeddu C; Massa E; Mudu MC; Mulas C; Gramignano G; Massidda S; Murgia V; Lusso MR; Mura L
    Int J Oncol; 2001 Feb; 18(2):383-91. PubMed ID: 11172608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depo-Provera use in an Australian metropolitan practice.
    Fraser IS; Dennerstein GJ
    Med J Aust; 1994 May; 160(9):553-6. PubMed ID: 8164553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical pharmacokinetics and practical consequences of optimal use of medroxyprogesterone acetate].
    Etienne MC; Milano G; Namer M
    Bull Cancer; 1993 May; 80(5):431-8. PubMed ID: 8173196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Menopause Study Group.
    Archer DF; Pickar JH; Bottiglioni F
    Obstet Gynecol; 1994 May; 83(5 Pt 1):686-92. PubMed ID: 8164926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability.
    Baracat EC; Barbosa IC; Giordano MG; Haidar MA; Marinho RM; Menegocci JC; Morais KM; Tomaz G; Wehba S
    Climacteric; 2002 Mar; 5(1):60-9. PubMed ID: 11974560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adolescents' reasons for and experience after discontinuation of the long-acting contraceptives Depo-Provera and Norplant.
    Harel Z; Biro FM; Kollar LM; Rauh JL
    J Adolesc Health; 1996 Aug; 19(2):118-23. PubMed ID: 8863083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and acceptability of depo-medroxyprogesterone acetate injection. As a method of contraception in Saudi Arabia.
    Sobande AA; Al-Bar HM; Archibong EI; Sadek AA
    Saudi Med J; 2000 Apr; 21(4):348-51. PubMed ID: 11533816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.